FIELD: medicine.
SUBSTANCE: described is a monoclonal antibody able to induce a specific biological reaction by its binding with the antigen CD20 on a cell surface. The monoclonal antibody showing high affine binding with an extracellular epitope of the antigen CD20, as well as biological activities including that directed on cell growth inhibition has been cloned. Said monoclonal antibody has been chimerised or humanised for the purpose of creating a therapeutic agent for treating a B-cell mediated disease.
EFFECT: invention expands a spectrum of the therapeutic agents prepared of the monoclonal anti-CB20-antibodies.
10 cl, 9 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATMENT, ANTIBODIES, HYBRIDOMA | 1993 |
|
RU2139731C1 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| PURIFICATION OF ANTIBODIES WITH CATION-EXCHANGE CHROMATOGRAPHY | 2008 |
|
RU2498991C2 |
| ILT17 ANTIBODY | 2006 |
|
RU2456298C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| ILT17 ANTIBODY | 2012 |
|
RU2599450C2 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| DEGRADED ANTIBODY AS TPO AGONIST | 2001 |
|
RU2287534C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
